These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 27754732)

  • 1. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy.
    Takashi Y; Kinoshita Y; Hori M; Ito N; Taguchi M; Fukumoto S
    Endocr Res; 2017 May; 42(2):132-137. PubMed ID: 27754732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
    Michigami T
    Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rickets/Osteomalacia. FGF23-related hypophosphatemic rickets/osteomalacia.].
    Fukumoto S
    Clin Calcium; 2018; 28(10):1313-1317. PubMed ID: 30269112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
    Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
    Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
    Fukumoto S
    Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted resequencing of phosphorus metabolism‑related genes in 86 patients with hypophosphatemic rickets/osteomalacia.
    Gu J; Wang C; Zhang H; Yue H; Hu W; He J; Fu W; Zhang Z
    Int J Mol Med; 2018 Sep; 42(3):1603-1614. PubMed ID: 29901142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.
    Hsu HJ; Wu MS
    Am J Med Sci; 2009 Feb; 337(2):116-22. PubMed ID: 19214027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FGF23-related hypophosphatemic rickets/osteomalacia].
    Ito N; Fukumoto S
    Clin Calcium; 2007 Oct; 17(10):1514-20. PubMed ID: 17906402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Updates on rickets and osteomalacia: anti-FGF23 antibody, a new therapeutic approach for hypophosphatemic rickets/osteomalacia].
    Shimada T
    Clin Calcium; 2013 Oct; 23(10):1469-75. PubMed ID: 24076645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
    Goldsweig BK; Carpenter TO
    Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
    Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
    Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.
    Mirza MA; Larsson A; Melhus H; Lind L; Larsson TE
    Atherosclerosis; 2009 Dec; 207(2):546-51. PubMed ID: 19524924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum fibroblast growth factor 23 is a useful marker to distinguish vitamin D-deficient rickets from hypophosphatemic rickets.
    Kubota T; Kitaoka T; Miura K; Fujiwara M; Ohata Y; Miyoshi Y; Yamamoto K; Takeyari S; Yamamoto T; Namba N; Ozono K
    Horm Res Paediatr; 2014; 81(4):251-7. PubMed ID: 24577200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
    Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
    Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical usefulness of the determination of fibroblast growth factor 23 in the evaluation of patients with osteomalacia].
    Gifre L; Martínez de Osaba MJ; Monegal A; Guañabens N; Peris P
    Med Clin (Barc); 2014 May; 142(10):447-50. PubMed ID: 24629692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients.
    Sarmento-Dias M; Santos-Araújo C; Poínhos R; Oliveira B; Silva IS; Silva LS; Sousa MJ; Correia F; Pestana M
    Clin Nephrol; 2016 Mar; 85(3):135-41. PubMed ID: 26833300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in understanding of phosphate homeostasis and related disorders.
    Michigami T
    Endocr J; 2022 Aug; 69(8):881-896. PubMed ID: 35831119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):170-175. PubMed ID: 38687287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.